title: VZV encephalitis that developed in an immunized patient during fingolimod therapy.
authors.affiliation: From The University of Chicago (N.P.I.); and NorthShore Neurological Institute (A.H.), NorthShore University Health System, Evanston, IL.
authors.forename: Naoum P
authors.initials: NP
authors.lastname: Issa
authors.affiliation: From The University of Chicago (N.P.I.); and NorthShore Neurological Institute (A.H.), NorthShore University Health System, Evanston, IL. ahentati@northshore.org.
authors.forename: Afif
authors.initials: A
authors.lastname: Hentati
mesh_terms: D020804:Encephalitis, Varicella Zoster / Q000139:chemically induced*; D005260:Female; D000068876:Fingolimod Hydrochloride; D053061:Herpes Zoster Vaccine / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy*; D011409:Propylene Glycols / Q000009:adverse effects*; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D053061:Herpes Zoster Vaccine; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine